The majority of plasma cell myelomas (PCMs) 
The majority of plasma cell myelomas (PCMs) CD200 is a member of the immunoglobulin type 1 superfamily that is highly expressed in the central nervous system, dendritic cells, and lymphocytes. 1,2 CD200 is functionally involved in an immunosuppressive signaling pathway via interaction with its receptor, CD200R, with downstream effects of macrophage inhibition, induction of regulatory T cells, and inhibition of tumor-specific T cells. 3, 4 In addition to being expressed in normal tissues, CD200 has also been demonstrated in solid tumors 5 and hematologic malignancies, such as acute leukemias, chronic lymphocytic leukemia/small lymphocytic lymphoma, hairy cell leukemia, mediastinal large B-cell lymphoma, classic Hodgkin lymphoma, and angioimmunoblastic T-cell lymphoma. [6] [7] [8] [9] [10] [11] [12] In addition, neoplastic plasma cells frequently upregulate CD200 expression, as demonstrated by the large proportion of CD200+ plasma cell myeloma (PCM) cases (approximately 70%) found on gene expression profiling and flow cytometry. 10, [12] [13] [14] In contrast, normal plasma cells are CD200-. 12, 14, 15 Although CD200 expression and stability has been studied using flow cytometry in cases of PCM, 10, [12] [13] [14] there are no flow cytometry data on CD200 expression in other, non-PCM immunoproliferative disorders, such as monoclonal gammopathy of undetermined significance (MGUS) and lymphoplasmacytic lymphoma (LPL). Flow cytometry immunophenotyping is an important tool in the diagnosis of monoclonal gammopathies and can be successfully used in the identification, immunophenotypic characterization, differential diagnosis, and minimal residual disease monitoring of these entities, particularly PCM. [16] [17] [18] [19] [20] [21] From a clinical perspective, MGUS is the most common plasma cell dyscrasia, Upon completion of this activity you will be able to:
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with an incidence of approximately 10% in patients older than 70 years. 22, 23 It is defined by the combination of serum monoclonal protein lower than 30 g/L, fewer than 10% clonal bone marrow plasma cells, absence of end-organ damage symptoms (hypercalcemia, renal failure, anemia, bone lesions), and no evidence of other diseases known to produce a monoclonal protein, such as a B-cell lymphoma. 22 The immunophenotypic features in MGUS, including flow cytometry markers of progression to PCM, are well documented, 19, [24] [25] [26] [27] and the flow cytometry profile of LPL has also been studied in significant detail. [28] [29] [30] In this study, we report the expression of CD200 by flow cytometry in patients with MGUS and LPL and correlate expression with clinicopathologic parameters. We also compare CD200 expression in the neoplastic plasma cells in these conditions with CD200 expression in newly diagnosed PCM cases. The data we describe are novel and, to the best of our knowledge, represent the first extensive immunophenotypic characterization of CD200 expression in nonmyeloma immunoproliferative disorders using flow cytometry. 31 and with diagnostic bone marrow biopsy specimens available for flow cytometry immunophenotyping were evaluated. All cases were analyzed by 4-color flow cytometry. Clinical and laboratory data were obtained from a review of medical records. The MCW institutional review board approved this study.
Materials and Methods

Patients
Flow Cytometry
Heparin-anticoagulated bone marrow aspirates were processed as previously described. 33 Samples were stained with antibodies conjugated to fluorescein isothiocyanate, phycoerythrin, peridinin chlorophyll protein, or allophycocyanin (APC). The following fluorochrome-conjugated monoclonal antibodies (BD Biosciences, San Jose, CA) were used: CD5 (L17F12), CD10 (W8E7), CD19 (SJ25C1), CD20 (L27), CD38 (HB7), CD45 (2D1), CD56 (MY31), CD117 (95C3), CD200 (OX-104), surface and cytoplasmic k (TB28-2), and surface and cytoplasmic l (1-55-2). At least 70,000 events were routinely acquired using either a FACSCalibur flow cytometer with CellQuest software (January to February 2009) or a FACSCanto II instrument with FACSDiva software (March 2009 to January 2012) (BD Biosciences). All analyses also included an isotype-matched control tube containing APC-labeled CD38 to establish the positive staining threshold for plasma cells.
Data Analysis
All data were analyzed using Paint-A-Gate Pro software (BD Biosciences). Distinct cell populations (clusters) were characterized using a combination of antibodies in conjunction with the CD45/side scatter and forward/side scatter characteristics. Neoplastic plasma cells and B cells were identified based on patterns of aberrant antigen expression and/or light chain restriction, defined as a k/l ratio greater than or equal to 5 or less than or equal to 0.5, as previously described. 33 A population was considered antigen positive when at least 20% of the cluster of interest exceeded a 2% isotype control cutoff. Because of the possibility of shifts in relative fluorescence over time related to instrument or reagent changes, when possible, levels of antigen expression were compared with additional internal normal cell populations.
Cytogenetic Analysis
Karyotyping and fluorescent in situ hybridization (FISH) were performed using previously reported methods 34 and molecular probes that detect common cytogenetic abnormalities in PCM (Vysis, Des Plaines, IL). Routine analysis included examination of at least 20 bone marrow cell metaphases and 200 interphase nuclei per DNA probe, respectively. Cases without abnormalities by conventional karyotype and FISH were classified as normal cytogenetics.
Statistical Analysis
Statistical analyses were carried out in GraphPad Prism, version 5.0b (GraphPad Software, San Diego, CA). Variables between groups were compared using Fisher exact and Student t tests; a P value less than .05 was considered statistically significant.
Results
Patient Characteristics
This study included 71 patients with MGUS and LPL. The MGUS cohort consisted of 32 men and 29 women with Downloaded from https://academic.oup.com/ajcp/article-abstract/138/6/867/1766502 by guest on 13 August 2018 a median age of 70 years (range, 44-88 years), and the LPL group consisted of 5 men and 5 women with a median age of 75 years (range, 55-87 years). ❚Table 1❚ summarizes the baseline clinical and laboratory features of these patients. All patients with MGUS and LPL had negative skeletal survey results and did not show other symptoms of end-organ damage related to the presence of the clonal plasma cell population. Based on the risk stratification model of predicting progression of MGUS to PCM or related disorders developed by Rajkumar et al, 35 25 .0% (7/28) high-intermediate risk. When comparing the 2 groups based on CD200 expression status, the distributions in the frequencies of the parameters examined were similar, with the exception of borderline significant differences in median age (P = .071) and bone marrow core biopsy cellularity (P = .063).
Flow Cytometric Findings and CD200 Expression in LPL
All 10 patients with LPL had light chain-restricted plasma cell and B-lymphocyte populations detected by flow cytometry at diagnosis, corresponding to the morphologic impression of a neoplastic infiltrate composed of small lymphocytes, plasma cells, and plasmacytoid lymphocytes ❚Image 2❚. The immunophenotypic characteristics of the plasma cells are presented in Table 1 CD200-, had more than 1 flow cytometry analysis, and all showed continued lack of CD200 expression in the plasma cells. CD200 could not be assessed in the LPL clonal B-cell populations because of the antibody combinations used.
Comparison of Immunophenotypic Characteristics and CD200 Expression in PCM, MGUS, and LPL
Of the 74 patients with PCM, 54 (73.0%) demonstrated CD200 expression on the neoplastic plasma cells ❚Image 3❚.
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❚Image 1❚ A, Immunophenotypic findings in a patient with CD200+ monoclonal gammopathy of undetermined significance (MGUS). Aberrant plasma cells (in red) are CD38+ (bright), CD19-, CD56+, CD200+, intracellular k+, and intracellular l-; they are also CD45-(not shown). B, Immunophenotypic findings in a patient with CD200-MGUS. Aberrant plasma cells (in red) are CD38+ (bright), CD19-, CD56-, CD200-, intracellular k+, and intracellular l-; they are also CD45-(not shown). An isotype control tube that contains CD38 allows comparison with nonspecific binding of mouse monoclonal antibodies. APC, allophycocyanin; Ig, immunoglobulin; PE, phycoerythrin. The proportion of CD200+ PCM cases was significantly higher than CD200+ MGUS cases (54.1%, P = .030) and LPLs (20%, P = .002). The median percentage of neoplastic plasma cells exceeding the isotype control threshold was 90% (range, 29%-100%) in CD200+ PCM cases, which was also higher than in CD200+ MGUS cases (58.5%, P = .004). No difference was seen in the frequency of cases with CD200+ plasma cells when comparing patients with MGUS vs LPL (P = .085). Other immunophenotypic features of the plasma cell clone were similar in MGUS and PCM (Table 1) , whereas the plasma cells in LPL were more likely to be CD19+, CD20+, CD45+, CD56-, and CD117-compared with PCM (P < .05 for all markers) ( Table 1) .
Discussion
We conducted a retrospective study of 61 patients with MGUS and 10 patients with LPL to investigate the flow cytometric expression of CD200 on neoplastic plasma cells in these conditions. Our results show that more than half of MGUS cases and one-fifth of LPL cases have CD200+ plasma cells.
We 14 and other authors 10, 12, 13 previously demonstrated CD200 positivity in a large proportion of PCMs (up to 78%) using flow cytometry, gene expression profiling, and/or immunohistochemistry. In our control cohort of 74 newly diagnosed cases of PCM in the present series, 73.0% were CD200+ on flow cytometric analysis, which is similar to the frequency (71%) reported in a recent flow cytometric study of 52 PCM cases. 12 CD200 expression appears to have prognostic significance in PCM because CD200-cases have a longer event-free survival, 13, 14 and loss of CD200 expression may serve as a marker for disease progression in PCM. 12 The proportion of PCM cases with CD200+ plasma cells was significantly higher than in MGUS and LPL. Notably, however, we did not find any difference in clinical and laboratory features between CD200+ and CD200-MGUS cases. In addition, a larger proportion of CD200+ plasma cells exceeded the isotype control threshold in CD200+ PCM cases than in CD200+ MGUS cases, indicating a higher density of CD200 antigen on plasma cells in the former. It may be hypothesized that the difference in CD200 expression between PCM and MGUS is related to the risk of patients with MGUS progressing to PCM or related disorders. The lifelong risk of transformation is approximately 1% per year, and the IMWG has recommended guidelines on risk stratification, monitoring, and treatment of patients with MGUS. 36 It is postulated that the lack of CD200 expression may void the deleterious effect of CD200-mediated suppression of the cytotoxic T-cell immune response. 3 It is therefore conceivable that patients with MGUS lacking CD200 are less likely to progress to PCM and perhaps select in this way for a higher proportion of CD200+ PCMs. Further study comparing the CD200 immunophenotype pre-and posttransformation to PCM may be warranted to support this theory. From a technical standpoint, the number of plasma cells detected by flow cytometry was lower than that estimated by morphology. As described by other authors, 17, 26, 27, 37 usually a lower percentage of plasma cells is detected by flow cytometry than by morphologic examination (approximately 5-to 10-fold difference, similar to our study). The reason for this decrement is likely multifactorial and includes heterogenous, patchy disease distribution in the bone marrow; A B ❚Image 2❚ A, Immunophenotypic findings in a patient with CD200+ lymphoplasmacytic lymphoma. Two aberrant clones are present: plasma cells (in red) are CD38+ (bright), CD19+, CD56-, CD45+, CD200+, intracellular k-, and intracellular l+; lymphocytes (in blue) are CD19+, CD20+, CD45+, CDD38+ (partial), surface k-, and surface l+. B, Immunophenotypic findings in a patient with CD200-lymphoplasmacytic lymphoma. Two aberrant clones are present: plasma cells (in red) are CD38+ (bright), CD19+, CD56-, CD45+, CD200-, intracellular k+, and intracellular l-; lymphocytes (in blue) are CD19+, CD20+, CD45+, CDD38-, surface k+, and surface l-. An isotype control tube that contains CD38 allows comparison with nonspecific binding of mouse monoclonal antibodies. APC, allophycocyanin; Ig, immunoglobulin; PE, phycoerythrin.
compared with cases with low frequencies. We have confirmed previous reports of aberrant antigen expression 17, 24, 25 on neoplastic plasma cells in our series of patients with MGUS. In all cases, the abnormal plasma cells were CD38+ hemodilution; and loss of plasma cells during specimen processing for flow cytometry. We did not find any differences in antigen expression and characteristics of cases with high frequencies of plasma cells in the flow cytometry analysis ❚Image 3❚ A, Immunophenotypic findings in a patient with CD200+ plasma cell myeloma. Aberrant plasma cells (in red) are CD38+ (bright), CD19-, CD56-, CD200+, intracellular k-, and intracellular l+; they are also CD45-(not shown). B, Immunophenotypic findings in a patient with CD200-plasma cell myeloma. Aberrant plasma cells (in red) are CD38+ (bright), CD19-, CD56+, CD200-, intracellular k-, and intracellular l+; they are also CD45-(not shown). An isotype control tube that contains CD38 allows comparison with nonspecific binding of mouse monoclonal antibodies. APC, allophycocyanin; Ig, immunoglobulin; PE, phycoerythrin. detected on plasma cells in a minority of cases (20%). The only immunophenotypic study of CD200 expression in LPL showed CD200 positivity in 8 of 10 cases analyzed with immunohistochemistry. 10 It is likely that CD200 expression was estimated in the B cells because no specific reference was made to plasma cells in that particular publication. An abstract from the same group with subsequent flow cytometric data reports CD200 positivity in LPL B cells in the majority of cases, albeit at lower intensity than that seen in chronic lymphocytic leukemia/small cell lymphocytic leukemia and hairy cell leukemia. 40 We were not able to assess CD200 expression on B cells in our series of LPL cases because of the lack of B-cell markers in the CD200 antibody tube used for flow cytometry. It would be of interest in the future to study the pattern of CD200 expression concomitantly in plasma cells and B cells in LPL, because it may provide additional clues on how flow cytometry may improve the diagnosis of this entity. Of note, the proportion of CD200+ IgM MGUS cases was similar to that of CD200+ LPL cases in our study, indicating a closer relationship between IgM MGUS and LPL, on the one hand, and IgG MGUS and PCM, on the other hand, based on this parameter.
In summary, we analyzed the pattern of CD200 expression in patients with nonmyeloma immunoproliferative disorders (MGUS and LPL) and compared it with CD200 expression in patients with PCM. To the best of our knowledge, this is the first extensive immunophenotypic characterization of CD200 expression in MGUS using flow cytometry. We confirm the high proportion of patients with CD200+ PCM noted on flow cytometry in other studies and show that both MGUS and LPL demonstrate CD200+ plasma cells at lower frequencies. These novel findings may have diagnostic significance, because they may improve the flow cytometric detection of abnormal clones in both LPL and MGUS. Future studies are required to elucidate the role of CD200 as a possible marker of progression in MGUS and to analyze the CD200 expression status in both the plasma cell and B-cell compartment of LPL.
(bright), and the majority of them demonstrated a CD19-, CD56+, CD20-, CD117-immunophenotype, with about half of the cases also being CD45+. The frequencies of the most common plasma cell aberrancies noted in our series are similar to those reported in the literature. 17, 19, 24, 25 In addition, because normal plasma cells do not express CD200, the CD200 expression in 52.4% of MGUS cases in our series constitutes an additional immunophenotypic aberrancy. Additional demographic, clinical, and laboratory characteristics were similar to those reported by other authors, with the exception of the proportion of cases with normal cytogenetic findings (91.8% in our series). Of 4 (12%) of 33 CD200+ MGUS cases with cytogenetic abnormalities, 2 had a t (11;14) , and the remaining 2 had a t(14;16) and trisomy 11. It is important to note that recent reports have identified a significant proportion (48%-56%) of common myeloma cytogenetic abnormalities with FISH in MGUS cases. 38, 39 However, those studies used plasma cell enrichment techniques before cytogenetic analysis, which was not performed in our patients. The risk stratification model proposed by Rajkumar et al 35 was applied to our patient cohort to estimate the relative risk of progression to PCM; although we found the number of cases falling in individual risk categories (low, low-intermediate, and high-intermediate) was similar to those reported by them, 35 our MGUS group had no high-risk patients. Also, none progressed to PCM during the follow-up period of this study.
The clinical and laboratory features of our group of LPL patients were similar to those reported by other authors. [28] [29] [30] We found a dual population of neoplastic plasma cells and B lymphocytes with the same light chain restriction in all 10 cases. Using flow cytometry, the plasma cells were CD38+ (bright), and the percentage detected was 1 order of magnitude lower than that estimated with morphologic study. The plasma cells were CD19+, CD45+, CD20+, and CD56-in the majority of LPLs, which is a similar immunophenotype to that reported in 2 well-characterized groups of LPL patients 28, 29 and distinct from typical plasma cell neoplasms that mostly lack CD19 and CD45, and are predominantly CD56+. The differential CD200 expression in PCM and LPL may represent an additional feature that distinguishes neoplastic plasma cells of true plasma cell malignancies (such as PCM) from plasma cells resulting from plasmacytic differentiation of indolent B-cell lymphomas. Three cases of LPL in our series had CD19-plasma cells. This immunophenotype has been sometimes associated with an IgG serum paraprotein, 28 but all of the patients with LPL in our study had an IgM monoclonal protein. The immunophenotype of the neoplastic B-cell clone was similar to that reported in other studies [28] [29] [30] and consisted of CD19+, CD20+, CD38+ (partial), CD5-, CD10-, CD23-, FMC-7-B lymphocytes in the majority of cases. CD200 expression was
